Summary Case histories from 20 patients undergoing postchemotherapy "second look" laparotomy for metastatic epithelial cell carcinoma of the ovary were reviewed in an attempt to evaluate the usefulness of this procedure and its likely impact on patient survival. The patient population comprised 18 patients treated with a combination of cisplatin, adriamycin and cyclophosphamide (PACe) and 2 patients treated with chlorambucil. The findings at second look were often predictable, and related to the adequacy of initial surgery. Complete tumour regression identified a group of patients with a relatively good prognosis. However in most patients residual tumour was found which rarely proved resectable. Second line chemotherapy was poorly tolerated, and appeared to have little impact on the disease particulary after combination chemotherapy had been used initially.
Metastatic epithelial cell carcinoma of the ovary characteristically remains confined to the abdominal cavity. The modern management of stage III or IV disease includes bilateral salpingooophorectomy, total abdominal hysterectomy (BSO + TAH) and omentectomy at initial exploratory surgery. In addition an attempt is made to debulk as effectively as possible residual metastatic disease (Griffiths 1975; Griffiths et al., 1979) . Following surgery chemotherapy is administered either as a single agent, or more recently as a drug combination (Young et al., 1978; Katz et al., 1981; Williams et al., 1982) . Evaluation of tumour response during this therapy is often difficult, and it is widely recognised that neither clinical examination nor the radiological procedures currently available are satisfactory to assess the effectiveness of treatment. Second look laparotomy, when first described in this context (Smith et al., 1976; Schwartz & Smith, 1980) was delayed until a complete clinical tumour remission had been obtained after multiple courses of alkylating agent therapy. Limitation of second look surgery to this defined (and relatively small) population has been associated with apparent clinical benefit; normal findings after a scrupulous search for tumour have predicted long term survival without further therapy. The findings of residual tumour allowed a change in therapy, perhaps improving survival.
More recently, and with the advent of combination chemotherapy, second look surgery (laparoscopy or laparotomy) has been used earlier in the clinical course, to date the time of complete remission and thereby decide the number of cycles of chemotherapy that need to be given (Young et al., 1978; Ozols et al., 1981; Oldham et al., 1982; Raju et al., 1982) . There is, however, no evidence to suggest that survival can be increased by use of these techniques, and in addition only scanty evidence exists that combination chemotherapy produces survival that is superior to single agents (Young et al., 1978; Katz et al., 1981; Pereira et al., 1981; Sturgeon et al., 1982; Carmo-Pereira et al., 1982; Vogl et al., 1982; Omura et al., 1983) . We have analysed our own experience of second look laparotomy in an attempt to evaluate its influence on our management of this relatively common disorder.
Materials and methods
The study population was unselected and consisted of patients undergoing second look laparoscopy or laparotomy for metastatic (FIGO Stage III or IV) Tumour response evaluation Tumour responses were recorded prior to second look surgery (on the basis of clinical and ultrasound examinations) and at the time of surgery. CT scanning was not available to us at the time of the series, and was not utilized in any patient. Response criteria were as follows: complete remission (CR), no clinical or radiological evidence of disease, partial remission (PR), greater than 50% decrease in the product of the cross sectional diameters of the tumour, stable disease (SD), less than 50% reduction in tumour mass, as defined, progressive disease (PD), increase in tumour size at any site. Equivocal CR (?CR) was a special categorisation applied to patients with abnormal, but biopsy negative findings at second look laparotomy.
Survival and disease-free survival were measured in months from the date of second look surgery. The following coding is used in the text for describing the present status of the patients; A =alive without disease, A+ =alive with disease, D°= dead without known disease at the time of death, D+ =dead with disease present.
Management of disease relapse Tumour relapse was documented by physical examination and/or ultrasound. Relapse was occasionally confirmed surgically, particularly when associated with either a prolonged disease free interval (and therefore potential resectability) or intestinal obstruction.
Further therapy was given at the discretion of the clinician, and was dependent on disease site and the patients general condition, however, patients treated primarily with chlorambucil were treated where possible with PACe chemotherapy, as were many of those in whom relapse from PACe occurred late.
Results
Twenty patients age range 44-68 years (mean 56) underwent a second procedure during this four year period. Sixteen patients were treated for FIGO stage III and four for FIGO stage IV disease (liver metastases 1, liver metastases and pleural effusion 1, pleural effusion only 2).
Six patients were treated with PACe before the randomised clinical study. The remaining fourteen patients were amongst those randomised in our current study. Two received oral chlorabucil, and the remaining twelve PACe induction chemotherapy (Table I ). These fourteen patients comprised 25% of the randomised study group of 55 patients, all of whom had completed six months therapy and were therefore eligible for a second look procedure. A further seven patients (13%) underwent laparoscopy rather than laparotomy as a restaging procedure. Partial tumour resection was possible in three patients, all of whom had received preoperative combination chemotherapy. These 3 patients died at 5, 7 and 9 months after second look surgery despite further combination chemotherapy.
In the remaining 7 patients the only procedure was biopsy of residual tumour masses.
Relationship offindings at second look surgery to initial operative procedure Six patients underwent successful bilateral salpingo oophorectomy and hysterectomy at initial exploratory surgery and 14 patients underwent either debulking only (7 patients) or biopsy only (7 patients). (Table III) (Reimer et al., 1977; Green et al., 1982) . These advantages are, however, theoretical and the ultimate test of the utility of this procedure is a clinical trial.
In practice the effect of second look surgery on patient survival has not itself been the subject of such a trial. Instead it has been widely utilised as a research tool, and has been recommended as a routine procedure in the management of this disease (Editorial, BMJ 1979).
These recommendations have been made on the basis of retrospective studies which were not specifically designed to test the usefulness of second look surgery. Smith et al., (1976) and Schwartz & Smith (1980) have the most extensive experience of late second-look surgery in ovarian carcinoma. Over a 14 year period (1960) (1961) (1962) (1963) (1964) (1965) (1966) (1967) (1968) (1969) (1970) (1971) (1972) (1973) (1974) 142 patients underwent second-look laparotomy. One hundred and twenty three (87%) of these patients were treated preoperatively with a single agent and the majority (90%) had stage III or IV disease. Unfortunately the authors do not provide adequate details of the (presumably large) number of patients with ovarian carcinoma from which this group is derived, although in an earlier report a figure of 800 patients is given. Thirty one patients (22%) were found to be disease free at second look surgery and only seven of these have subsequently relapsed, although follow up on many patients is short. A striking relationship was found between the number of cycles of chemotherapy given prior to second look surgery, and the incidence of residual disease found at surgery (14.6% negative second look after 2-9 courses of melphalan; 43.7% for > 10 courses of melphalan). (Young et al., 1978; Oldham et al., 1982; Raju et al., 1982 A relatively common result of these procedures, not alluded to in the literature was that the findings were equivocal at surgery; many patients with initial gross tumour were found to have dense abdominal and/or pelvic adhesions with poor planes of cleavage and surgery proved technically difficult. Despite negative biopsies, relapse occurred in 4 of 5 such patients and close follow up is clearly mandatory.
We have not been able to demonstrate any convincing role for resection at second look surgery, and the very poor prognosis of those patients found to have residual disease highlights the inefficacy of second line or alternative chemotherapy or radiotherapy. Indeed in many cases further therapy post surgery or at relapse was seriously compromised by patient preference, toxicity from initial therapy, or poor tolerance after surgery. These data would also argue against the use of chemotherapy to debulk tumour prior to initial surgery.
Laparoscopy is a seemingly more attractive procedure than laparotomy as there is less morbidity and it can be repeated more frequently. However it is clearly less accurate than laparotomy; a number of centres (Smith et al., 1977; Ozols et al., 1981) have performed laparotomy immediately after negative laparoscopy, and have been able to identify residual tumour in approximately 50% of cases. A probably useful role for this procedure is a preliminary to laparotomy. Patients with gross, unresectable disease may then be spared formal exploratory surgery.
We feel that early second look operations, whilst to some extent identifying prognostic groups, probably had little influence on therapy or on ultimate survival. We would recommend that routine early second laparotomy should be confined to a clinical trial setting until a survival benefit has been shown to result from this procedure. Trials testing the role of early second look surgery are needed; these should be designed to test whether a second look operation in the setting of a flexible chemotherapy regime will result in more CR's and prolonged survival.
Those few patients on treatment who remain in long term CR may, can be considered for second look laparoscopy, and if this negative, laparotomy, in an attempt to reduce the incidence of treatment related leukaemia. Patients with residual disease should continue with long term therapy and those in CR can probably discountinue treatment, and be watched carefully for disease relapse.
